-
公开(公告)号：US10377770B2
公开(公告)日：2019-08-13
申请号：US16062680
申请日：2016-12-15
申请人： Novartis AG
发明人： Robert John Aversa , Matthew T. Burger , Michael Patrick Dillon , Thomas A. Dineen, Jr. , Rajesh Karki , Savithri Ramurthy , Vivek Rauniyar , Richard Robinson , Patrick James Sarver
IPC分类号： C07D487/04 , C07D491/04 , C07D498/04 , A61P35/00 , C07D491/044
摘要： The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
-
公开(公告)号：US10167279B2
公开(公告)日：2019-01-01
申请号：US15510609
申请日：2015-09-11
申请人： NOVARTIS AG
发明人： Robert John Aversa , Matthew T. Burger , Michael Patrick Dillon , Thomas A. Dineen, Jr. , Yan Lou , Gisele A. Nishiguchi , Savithri Ramurthy , Alice C. Rico , Vivek Rauniyar , Martin Sendzik , Sharadha Subramanian , Lina Quattrocchio Setti , Benjamin R. Taft , Huw Rowland Tanner , Lifeng Wan
IPC分类号： C07D405/14 , C07D405/12 , C07D305/06 , A61P35/00 , C07D413/14
摘要： The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US10392404B2
公开(公告)日：2019-08-27
申请号：US15510613
申请日：2015-09-11
申请人： NOVARTIS AG
发明人： Paul Andrew Barsanti , Matthew T. Burger , Yan Lou , Gisele A. Nishiguchi , Valery Rostislavovich Polyakov , Savithri Ramurthy , Sharadha Subramanian , Benjamin R. Taft , Huw Rowland Tanner , Lifeng Wan
IPC分类号： A61K31/444 , C07D498/08 , C07D401/14 , C07D413/14 , C07D213/74 , C07D401/04 , C07D401/10 , C07D407/14 , C07D411/14 , C07D413/12 , A61K31/4418 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K31/541 , C07D213/85 , C07D405/12 , C07D405/14 , C07D451/02
摘要： The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US10245267B2
公开(公告)日：2019-04-02
申请号：US15601423
申请日：2017-05-22
申请人： NOVARTIS AG
发明人： Robert John Aversa , Paul Andrew Barsanti , Matthew T. Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele A. Nishiguchi , Yue Pan , Valery Rostislavovich Polyakov , Savithri Ramurthy , Alice C. Rico , Lina Quattrocchio Setti , Aaron Smith , Sharadha Subramanian , Benjamin R. Taft , Huw Roland Tanner , Lifeng Wan , Naeem Yusuff
IPC分类号： C07D295/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D401/04 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048 , A61K31/444 , A61K31/501 , C07B59/00 , C07D237/24 , C07D491/04 , C07D491/08
摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US09242969B2
公开(公告)日：2016-01-26
申请号：US14204823
申请日：2014-03-11
申请人： Novartis AG
发明人： Paul A. Barsanti , Matthew Burger , Yan Lou , Gisele Nishiguchi , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Benjamin Taft , Huw Tanner , Alan DiPesa , Naeem Yusuff
IPC分类号： C07D401/04 , C07D403/04 , A61K31/5377 , A61K31/541 , C07D413/04 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04
CPC分类号： A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
摘要翻译： 本发明提供了本文所述的式（I）化合物及其盐，以及这些化合物治疗与Raf激酶活性相关的疾病的治疗用途。 本发明还提供包含这些化合物的药物组合物，以及包含这些化合物和治疗性助剂的组合物。
-
公开(公告)号：US10709712B2
公开(公告)日：2020-07-14
申请号：US16274165
申请日：2019-02-12
申请人： NOVARTIS AG
发明人： Robert John Aversa , Paul Andrew Barsanti , Matthew T. Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele A. Nishiguchi , Yue Pan , Valery Rostislavovich Polyakov , Savithri Ramurthy , Alice C. Rico , Lina Quattrocchio Setti , Aaron Smith , Sharadha Subramanian , Benjamin R. Taft , Huw Roland Tanner , Lifeng Wan , Naeem Yusuff
IPC分类号： A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D401/04 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048 , A61K31/444 , A61K31/501 , C07B59/00 , C07D237/24 , C07D491/04 , C07D491/08
摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US09694016B2
公开(公告)日：2017-07-04
申请号：US14774431
申请日：2014-03-13
申请人： Novartis AG
发明人： Robert John Aversa , Paul Andrew Barsanti , Matthew Burger , Michael Patrick Dillon , Alan Dipesa , Cheng Hu , Yan Lou , Gisele Nishiguchi , Yue Pan , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Sharadha Subramanian , Benjamin Taft , Huw Tanner , Lifeng Wan , Naeem Yusuff
IPC分类号： C07D413/14 , C07D403/14 , C07D403/12 , C07D401/04 , A61K31/5377 , C07D413/04 , A61K31/541 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D403/04 , C07D413/12 , C07D417/12 , C07D493/10 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D491/048
CPC分类号： A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
摘要： The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.032 秒)
